Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921404 | 1.00 | TNKS (0.34) | TNKSCHRNB2CHRNA4HPGDSCHRNB4 | |
| SCHEMBL29966596 | 1.00 | TNKS (0.34) | TNKSCHRNB2CHRNA4HPGDSCHRNB4 | |
| SCHEMBL29641343 | 1.00 | TNKS (0.34) | TNKSCHRNB2CHRNA4HPGDSCHRNB4 | |
| SCHEMBL22444813 | 1.00 | TNKS (0.34) | TNKSCHRNB2CHRNA4HPGDSCHRNB4 | |
| Trifluoroacetic Acid SCHEMBL29048254 | 0.86 | GPR6 (0.33) | TNKSCHRNB2CHRNA4 | |
| SCHEMBL18921319 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL29966490 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL18921312 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL29966900 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL25816442 | 0.79 | DRD2 (0.43) | TNKSCHRNB2CHRNA4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4709722-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233547-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | SANOFI (FR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023068881-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | 주식회사 보로노이바이오 | 2023-04-27 | — | — | WO | disclosed |
| WO-2022131741-A1 | ISOXAZOLIDINE DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-06-23 | — | — | WO | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020235902-A1 | HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | 주식회사 보로노이 (KR) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020149553-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR TREATMENT OF KINASE-RELATED DISEASE | 주식회사 보로노이 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219937-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK4, RIPK2 | TNKS 169/4885CHRNB2 4268/4885CHRNA4 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.